ABBOTT PARK, Ill., March 6, 2019 /PRNewswire/ -- Key medical devices across Abbott's (NYSE: ABT) cardiovascular portfolio will be highlighted in five late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session (ACC 2019) from March 16 – 18 in New Orleans. The late-breaking studies showcase the depth and breadth of the company's cardiovascular portfolio, providing new data on outcomes with the following products: the MitraClip™ system for transcatheter mitral valve repair, the HeartMate 3™ heart pump, the CardioMEMS™ HF System for proactive heart failure monitoring, and the XIENCE drug eluting coronary stent.
Late-breaking data at the American College of Cardiology Scientific Sessions can change clinical practice and impact the way new therapies are accepted and utilized to improve patient care. For Abbott, ACC 2019 provides an opportunity to demonstrate how the company's therapies have led to dramatic improvements in the treatment of cardiovascular diseases. Data from these late-breaking trials may help physicians rethink what is possible in managing patients with coronary artery disease and heart failure.
"Heart disease impacts far too many patients and families worldwide," said Mark Carlson, M.D., divisional vice president and chief medical officer, Cardiac Arrhythmias and Heart Failure, Abbott. "Across Abbott we focus every day on developing the next breakthroughs in cardiovascular care. At ACC, we're excited to showcase several of our best-in-class technologies that are shaping how healthcare providers care for people with heart disease."
During ACC 2019, the following late-breaking data on Abbott technology will be presented in the Main Tent (Great Hall):
- The COAPT™ Trial on MitraClip (Sunday, March 17; 8:45 – 8:55 a.m. and 9:00 – 9:10 a.m. CT)
Two late-breaking data presentations will provide new echocardiographic and quality-of-life insights from the landmark COAPT Trial. The new data will further bolster COAPT data originally published inThe New England Journal of Medicine in 2018, which assessed the impact of transcatheter mitral valve repair with MitraClip in patients with heart failure and secondary mitral regurgitation.
Initial data from the COAPT Trial was groundbreaking within the medical community, and showed MitraClip was superior to medical therapy for treating select heart failure patients with significant secondary mitral regurgitation, a patient population that has been historically challenging for physicians to treat. The study met its primary safety and efficacy endpoints and all ten secondary endpoints.
- MOMENTUM 3 data on HeartMate 3 (Sunday, March 17; 11:30 – 11:40 a.m. CT)
In the full cohort analysis of the MOMENTUM 3 study, researchers will present two-year survival and adverse event data for all 1,028 study participants who received either Abbott's HeartMate 3 heart pump or Abbott's HeartMate II. Since its launch, the HeartMate 3 heart pump has built upon the success of the HeartMate II, the previous gold standard in mechanical circulatory support.
Last year, MOMENTUM 3 data published in The New England Journal of Medicine included a two-year follow-up with a subset of 366 patients and showed patients receiving a HeartMate 3 benefited from best-in-class survival and the lowest published rates of stroke and thrombosis (blood clots). MOMENTUM 3 is the world's largest randomized controlled study of left ventricular assist device (LVAD) therapy to date.
- CardioMEMS Post Approval Study (Sunday, March 17; 11:45 – 11:55 a.m. CT)
In Abbott's CardioMEMS Post Approval Study (PAS), researchers will present one-year outcomes associated with the world's first and only approved pulmonary pressure sensor. To date, data for the CardioMEMS HF System has been shown to yield significant reductions in heart failure rehospitalization for people with NYHA Class III heart failure.
Abbott's CardioMEMS HF System has fundamentally changed how physicians can monitor and treat heart failure by allowing physicians to remotely monitor changes in pulmonary pressure – a sign of worsening heart failure – before symptoms progress. This personalized approach allows physicians to more proactively manage a patient's care while reducing the likelihood of hospitalization.
- STOPDAPT-2 with XIENCE (Monday, March 18; 11:30 – 11:40 a.m. CT)
An independent investigator-sponsored study from Japan, STOPDAPT-2 evaluated 3,009 patients treated with dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) procedures with XIENCE at one month versus 12 months. The new data from this prospective, multicenter, randomized study will further the medical community's understanding around the possibility of decreasing the duration of these medications that can reduce clotting but also carry a risk of increased bleeding.
To further evaluate optimal DAPT duration, Abbott is currently enrolling patients in the company's XIENCE 90 and XIENCE 28 trials to investigate the safety and efficacy of stenting procedures followed by shorter-than-conventional duration of DAPT.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
View original content:http://www.prnewswire.com/news-releases/late-breaking-data-presentations-at-acc-2019-highlight-abbotts-leading-cardiovascular-portfolio-300807462.html